ONCT News and Press, Oncternal Therapeutics Inc. From 03/11/20

50% (six of twelve) evaluable patients with relapsed/refractory MCL achieved complete responses (CR) in the dose-finding cohort of the ongoing Phase 1/2 clinical trial 83% best objective response rate (ORR) and 100% clinical benefit rate Oncternal Therapeutics, Inc. (Nasdaq: ...

- Anti-ROR1 CAR-T cell therapy demonstrated expansion, persistence and anti-tumor activity in animal model of human leukemia Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced t...

- Four of seven evaluable patients with HER2-negative, metastatic or locally-advanced unresectable breast cancer achieved a partial response for an objective response rate of 57% - Cirmtuzumab in combination with paclitaxel has been well tolerated Oncternal Therapeutics, Inc. (Nas...

Dose-finding cohort demonstrated clinical activity and was generally well-tolerated TK216 has been granted Orphan Drug and Fast Track Designations for treatment of patients with relapsed/refractory Ewing sarcoma Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage b...

The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this Read more ...

Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100% Cirmtuzumab has been very well tolerated in this trial Inhibition of ROR1 signaling by cirmtuzumab was shown to reverse gene expression signatur...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...